|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
4,540,000 |
Market
Cap: |
17.07(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.15 - $6.931 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aileron Therapeutics is a clinical stage chemoprotection oncology company. ALRN-6924, Co.'s MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. Co.'s clinical development program for ALRN-6924 as a selective chemoprotective agent includes: Its completed Phase 1b open-label clinical trial evaluating ALRN-6924 as a chemoprotective agent in patients with p53-mutated small cell lung cancer, undergoing treatment with second-line topotecan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
5,301 |
5,301 |
5,301 |
Total Buy Value |
$0 |
$10,745 |
$10,745 |
$10,745 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
2 |
2 |
2 |
Total Shares Sold |
31,151 |
31,151 |
31,151 |
31,151 |
Total Sell Value |
$139,103 |
$139,103 |
$139,103 |
$139,103 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
3 |
3 |
3 |
3 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
University Of Texas/texas Am Investment Managment |
10% Owner |
|
2024-05-01 |
4 |
S |
$4.10 |
$85,473 |
D/D |
(20,315) |
1,779,306 |
|
8% |
|
University Of Texas/texas Am Investment Managment |
10% Owner |
|
2024-04-30 |
4 |
S |
$4.95 |
$448 |
D/D |
(90) |
1,799,621 |
|
16% |
|
University Of Texas/texas Am Investment Managment |
10% Owner |
|
2024-04-29 |
4 |
S |
$4.92 |
$53,182 |
D/D |
(10,746) |
1,799,711 |
|
22% |
|
Windsor James Brian |
President and COO |
|
2024-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,000 |
7,122 |
|
- |
|
University Of Texas/texas Am Investment Managment |
10% Owner |
|
2024-02-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,810,457 |
|
-19% |
|
Windsor James Brian |
President and COO |
|
2023-12-15 |
4 |
B |
$3.37 |
$758 |
I/I |
225 |
225 |
0.01 |
29% |
|
Windsor James Brian |
President and COO |
|
2023-11-20 |
4 |
B |
$1.97 |
$9,987 |
D/D |
5,076 |
5,122 |
0.01 |
220% |
|
Windsor James Brian |
See RemarksOfficer |
|
2023-10-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46 |
|
349% |
|
Satter Muneer A |
See Remarks |
|
2021-01-08 |
4 |
B |
$1.10 |
$9,900,000 |
I/I |
9,000,000 |
16,609,449 |
2.66 |
-12% |
|
Ambros Reinhard J. |
Director |
|
2020-06-15 |
4 |
B |
$1.22 |
$7,076 |
D/D |
5,800 |
5,800 |
2.39 |
17% |
|
Von Rickenbach Josef H |
Director |
|
2020-06-08 |
4 |
B |
$1.10 |
$249,999 |
D/D |
227,272 |
445,460 |
2.39 |
47% |
|
Satter Muneer A |
See Remarks |
|
2020-06-08 |
4 |
B |
$1.10 |
$4,070,000 |
I/I |
3,700,000 |
7,609,449 |
2.25 |
47% |
|
Bailey Jeffrey Allen |
Director |
|
2019-11-15 |
4 |
B |
$0.51 |
$19,962 |
D/D |
39,142 |
74,894 |
2.39 |
- |
|
Bailey Jeffrey Allen |
Director |
|
2019-11-14 |
4 |
B |
$0.51 |
$8,088 |
D/D |
15,858 |
35,752 |
2.39 |
- |
|
Bailey Jeffrey Allen |
Director |
|
2019-11-12 |
4 |
B |
$0.53 |
$10,544 |
D/D |
19,894 |
19,894 |
2.39 |
- |
|
Von Rickenbach Josef H |
Director |
|
2019-09-13 |
4 |
B |
$0.97 |
$24,255 |
D/D |
25,000 |
218,188 |
2.39 |
- |
|
Von Rickenbach Josef H |
Director |
|
2019-09-12 |
4 |
B |
$0.98 |
$86,250 |
D/D |
88,145 |
193,188 |
2.39 |
- |
|
Von Rickenbach Josef H |
Director |
|
2019-09-04 |
4 |
B |
$0.71 |
$16,583 |
D/D |
23,225 |
105,043 |
2.39 |
- |
|
Von Rickenbach Josef H |
Director |
|
2019-09-03 |
4 |
B |
$0.70 |
$9,428 |
D/D |
13,466 |
81,818 |
2.39 |
- |
|
Von Rickenbach Josef H |
Director |
|
2019-08-30 |
4 |
B |
$0.73 |
$10,968 |
D/D |
15,000 |
68,352 |
2.39 |
- |
|
Von Rickenbach Josef H |
Director |
|
2019-08-29 |
4 |
B |
$0.77 |
$2,771 |
D/D |
3,600 |
53,352 |
2.31 |
- |
|
Vukovic Vojo |
SVP, Chief Medical Officer |
|
2019-08-16 |
4 |
B |
$0.59 |
$44,453 |
D/D |
75,000 |
75,000 |
2.74 |
- |
|
Gregory Kathryn |
SVP, Chief Business Officer |
|
2019-08-13 |
4 |
B |
$0.65 |
$29,025 |
D/D |
45,000 |
45,000 |
2.74 |
- |
|
Von Rickenbach Josef H |
Director |
|
2019-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
49,752 |
|
- |
|
Satter Muneer A |
10% Owner |
|
2019-04-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,909,449 |
|
- |
|
104 Records found
|
|
Page 1 of 5 |
|
|